Targeting mitochondrial dysfunction in the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a clinical audit.
Myhill, Sarah, Booth, Norman E, McLaren-Howard, John · International journal of clinical and experimental medicine · 2013
Quick Summary
This study looked at 138 ME/CFS patients and found that all of them had problems with their mitochondria—the parts of cells that produce energy. Patients received personalized treatment based on diet, sleep, supplements, and rest-activity balance, adjusted according to their specific mitochondrial problems. Those who followed the full treatment plan improved their mitochondrial function by about four times on average.
Why It Matters
This research provides evidence that mitochondrial dysfunction is present across ME/CFS populations and suggests that targeted interventions addressing energy metabolism may produce measurable biochemical improvements. The finding that treatment adherence correlates with mitochondrial recovery offers practical insights for patients considering lifestyle and supplementation strategies.
Observed Findings
All 138 patients tested showed measurable mitochondrial dysfunction on ATP Profile testing.
30 patients who fully adhered to the treatment protocol showed approximately 4-fold average improvement in mitochondrial function parameters.
4 patients with poor adherence (lax on 2+ treatment aspects) showed notably lower improvement.
Case histories documented individual mitochondrial recovery patterns across repeated testing occasions.
Inferred Conclusions
The authors conclude that mitochondrial dysfunction is a consistent biomarker in ME/CFS populations.
They infer that targeted nutritional and lifestyle interventions can restore mitochondrial function when patients maintain full treatment adherence.
The authors propose that mitochondrial impairment occurs through two main mechanisms—nutrient deficiency and chemical inhibition—requiring differentiated treatment approaches.
Remaining Questions
Do improvements in mitochondrial function measured by ATP Profile correlate with symptomatic recovery and functional capacity gains?
How do these results compare to ME/CFS patients receiving standard care or placebo interventions?
Which components of the multi-faceted treatment protocol drive the most significant mitochondrial recovery?
What This Study Does Not Prove
This study does not establish causation—it cannot prove that improving mitochondrial function causes symptom improvement or recovers ME/CFS. The lack of a control group, unblinded design, and small high-adherence subgroup (n=30) limit generalizability. It does not demonstrate that ATP Profile-guided treatment is superior to other approaches or that improvements translate to functional recovery.
Tags
Symptom:Unrefreshing SleepFatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionNo ControlsSmall SampleExploratory Only